| 1 | adversely | 1,252 |
| 2 | evoked | 1,229 |
| 3 | manifest | 827 |
| 4 | favorably | 749 |
| 5 | event-related | 385 |
| 6 | favourably | 336 |
| 7 | beneficially | 176 |
| 8 | materially | 86 |
| 9 | heat-evoked | 61 |
| 10 | motor-evoked | 49 |
| 11 | unfavorably | 31 |
| 12 | unduly | 30 |
| 13 | detrimentally | 25 |
| 14 | auditory-evoked | 22 |
| 15 | psammoma | 20 |
| 16 | unfavourably | 18 |
| 17 | visual-evoked | 13 |
| 18 | deleteriously | 12 |
| 19 | laser-evoked | 12 |
| 20 | sensory-evoked | 7 |
| 21 | somatosensory-evoked | 7 |
| 22 | regimen-specific | 6 |
| 23 | high-average | 4 |
| 24 | mallory-denk | 3 |
| 25 | allele-specifically | 2 |
| 26 | anthropomorphism | 2 |
| 27 | commissuration | 2 |
| 28 | fixed-avd | 2 |
| 29 | foment | 2 |
| 30 | nt-3-induced | 2 |
| 31 | p97/vcp | 2 |
| 32 | pleiotropically | 2 |
| 33 | rizzo | 2 |
| 34 | stress-reactivity | 2 |
| 35 | thermal/visceral | 2 |
| 36 | virus-inactivated | 2 |
| 37 | 'horizon | 1 |
| 38 | 'postoperative | 1 |
| 39 | -mof-5 | 1 |
| 40 | -substituents | 1 |
| 41 | 14-3-3ɛ/ζ | 1 |
| 42 | 2,545 | 1 |
| 43 | 2004/05 | 1 |
| 44 | 5-ht1a-agonism | 1 |
| 45 | 5asa | 1 |
| 46 | 5hre-sv40mp | 1 |
| 47 | adenosine-3',5'-cyclic | 1 |
| 48 | amplitude-associated | 1 |
| 49 | anagrelide/aspirin | 1 |
| 50 | aversively | 1 |
| 51 | benefically | 1 |
| 52 | beta4-containing | 1 |
| 53 | better-established | 1 |
| 54 | carbonyl-based | 1 |
| 55 | cephalosporins/quinolones | 1 |
| 56 | ceratophyus | 1 |
| 57 | cin3/cancers | 1 |
| 58 | crt-p/crt-d | 1 |
| 59 | cyp2j2/eets | 1 |
| 60 | deficity | 1 |
| 61 | during-behavior | 1 |
| 62 | event-prone | 1 |
| 63 | factor=2.80 | 1 |
| 64 | goitrogenic/antithyroidal | 1 |
| 65 | gradient-induced | 1 |
| 66 | grant-providing | 1 |
| 67 | guanylylation | 1 |
| 68 | guided-behavior | 1 |
| 69 | here-significantly | 1 |
| 70 | hyperdensity/hyperintensity | 1 |
| 71 | inter-lead | 1 |
| 72 | k293 | 1 |
| 73 | low-average/low | 1 |
| 74 | lycopene-can | 1 |
| 75 | malnet-treatment | 1 |
| 76 | mdm2-inhibition | 1 |
| 77 | medication-review | 1 |
| 78 | milligravity | 1 |
| 79 | mixed-evoked | 1 |
| 80 | mmis | 1 |
| 81 | most-commonly | 1 |
| 82 | multicargotransporters | 1 |
| 83 | multitrials | 1 |
| 84 | necessarly | 1 |
| 85 | negative-polarity | 1 |
| 86 | neurofeedback-enhanced | 1 |
| 87 | non-glutamate | 1 |
| 88 | non-homeostatically | 1 |
| 89 | pathogen-recognition | 1 |
| 90 | post-deep | 1 |
| 91 | pre-operative- | 1 |
| 92 | predminantly | 1 |
| 93 | protiens | 1 |
| 94 | reworkability | 1 |
| 95 | scale-fine | 1 |
| 96 | self-mobilization | 1 |
| 97 | slit2n/robo4 | 1 |
| 98 | spa-treatment | 1 |
| 99 | speed/set | 1 |
| 100 | system-is | 1 |
| 101 | tlr2-triggering | 1 |
| 102 | trial,19 | 1 |
| 103 | tulathramycin | 1 |
| 104 | whithout | 1 |
| 1 | 'horizon | 1 |
| 2 | 'postoperative | 1 |
| 3 | -mof-5 | 1 |
| 4 | -substituents | 1 |
| 5 | 14-3-3ɛ/ζ | 1 |
| 6 | 2,545 | 1 |
| 7 | 2004/05 | 1 |
| 8 | 5-ht1a-agonism | 1 |
| 9 | 5asa | 1 |
| 10 | 5hre-sv40mp | 1 |
| 11 | adenosine-3',5'-cyclic | 1 |
| 12 | adversely | 1,252 |
| 13 | allele-specifically | 2 |
| 14 | amplitude-associated | 1 |
| 15 | anagrelide/aspirin | 1 |
| 16 | anthropomorphism | 2 |
| 17 | auditory-evoked | 22 |
| 18 | aversively | 1 |
| 19 | benefically | 1 |
| 20 | beneficially | 176 |
| 21 | beta4-containing | 1 |
| 22 | better-established | 1 |
| 23 | carbonyl-based | 1 |
| 24 | cephalosporins/quinolones | 1 |
| 25 | ceratophyus | 1 |
| 26 | cin3/cancers | 1 |
| 27 | commissuration | 2 |
| 28 | crt-p/crt-d | 1 |
| 29 | cyp2j2/eets | 1 |
| 30 | deficity | 1 |
| 31 | deleteriously | 12 |
| 32 | detrimentally | 25 |
| 33 | during-behavior | 1 |
| 34 | event-prone | 1 |
| 35 | event-related | 385 |
| 36 | evoked | 1,229 |
| 37 | factor=2.80 | 1 |
| 38 | favorably | 749 |
| 39 | favourably | 336 |
| 40 | fixed-avd | 2 |
| 41 | foment | 2 |
| 42 | goitrogenic/antithyroidal | 1 |
| 43 | gradient-induced | 1 |
| 44 | grant-providing | 1 |
| 45 | guanylylation | 1 |
| 46 | guided-behavior | 1 |
| 47 | heat-evoked | 61 |
| 48 | here-significantly | 1 |
| 49 | high-average | 4 |
| 50 | hyperdensity/hyperintensity | 1 |
| 51 | inter-lead | 1 |
| 52 | k293 | 1 |
| 53 | laser-evoked | 12 |
| 54 | low-average/low | 1 |
| 55 | lycopene-can | 1 |
| 56 | mallory-denk | 3 |
| 57 | malnet-treatment | 1 |
| 58 | manifest | 827 |
| 59 | materially | 86 |
| 60 | mdm2-inhibition | 1 |
| 61 | medication-review | 1 |
| 62 | milligravity | 1 |
| 63 | mixed-evoked | 1 |
| 64 | mmis | 1 |
| 65 | most-commonly | 1 |
| 66 | motor-evoked | 49 |
| 67 | multicargotransporters | 1 |
| 68 | multitrials | 1 |
| 69 | necessarly | 1 |
| 70 | negative-polarity | 1 |
| 71 | neurofeedback-enhanced | 1 |
| 72 | non-glutamate | 1 |
| 73 | non-homeostatically | 1 |
| 74 | nt-3-induced | 2 |
| 75 | p97/vcp | 2 |
| 76 | pathogen-recognition | 1 |
| 77 | pleiotropically | 2 |
| 78 | post-deep | 1 |
| 79 | pre-operative- | 1 |
| 80 | predminantly | 1 |
| 81 | protiens | 1 |
| 82 | psammoma | 20 |
| 83 | regimen-specific | 6 |
| 84 | reworkability | 1 |
| 85 | rizzo | 2 |
| 86 | scale-fine | 1 |
| 87 | self-mobilization | 1 |
| 88 | sensory-evoked | 7 |
| 89 | slit2n/robo4 | 1 |
| 90 | somatosensory-evoked | 7 |
| 91 | spa-treatment | 1 |
| 92 | speed/set | 1 |
| 93 | stress-reactivity | 2 |
| 94 | system-is | 1 |
| 95 | thermal/visceral | 2 |
| 96 | tlr2-triggering | 1 |
| 97 | trial,19 | 1 |
| 98 | tulathramycin | 1 |
| 99 | unduly | 30 |
| 100 | unfavorably | 31 |
| 101 | unfavourably | 18 |
| 102 | virus-inactivated | 2 |
| 103 | visual-evoked | 13 |
| 104 | whithout | 1 |
| 1 | pre-operative- | 1 |
| 2 | factor=2.80 | 1 |
| 3 | k293 | 1 |
| 4 | slit2n/robo4 | 1 |
| 5 | -mof-5 | 1 |
| 6 | 2004/05 | 1 |
| 7 | 2,545 | 1 |
| 8 | trial,19 | 1 |
| 9 | psammoma | 20 |
| 10 | 5asa | 1 |
| 11 | regimen-specific | 6 |
| 12 | adenosine-3',5'-cyclic | 1 |
| 13 | crt-p/crt-d | 1 |
| 14 | inter-lead | 1 |
| 15 | neurofeedback-enhanced | 1 |
| 16 | nt-3-induced | 2 |
| 17 | gradient-induced | 1 |
| 18 | better-established | 1 |
| 19 | evoked | 1,229 |
| 20 | mixed-evoked | 1 |
| 21 | visual-evoked | 13 |
| 22 | laser-evoked | 12 |
| 23 | motor-evoked | 49 |
| 24 | heat-evoked | 61 |
| 25 | sensory-evoked | 7 |
| 26 | somatosensory-evoked | 7 |
| 27 | auditory-evoked | 22 |
| 28 | carbonyl-based | 1 |
| 29 | amplitude-associated | 1 |
| 30 | event-related | 385 |
| 31 | virus-inactivated | 2 |
| 32 | fixed-avd | 2 |
| 33 | high-average | 4 |
| 34 | scale-fine | 1 |
| 35 | event-prone | 1 |
| 36 | non-glutamate | 1 |
| 37 | 'postoperative | 1 |
| 38 | grant-providing | 1 |
| 39 | beta4-containing | 1 |
| 40 | tlr2-triggering | 1 |
| 41 | mallory-denk | 3 |
| 42 | goitrogenic/antithyroidal | 1 |
| 43 | thermal/visceral | 2 |
| 44 | anthropomorphism | 2 |
| 45 | 5-ht1a-agonism | 1 |
| 46 | lycopene-can | 1 |
| 47 | tulathramycin | 1 |
| 48 | anagrelide/aspirin | 1 |
| 49 | guanylylation | 1 |
| 50 | commissuration | 2 |
| 51 | self-mobilization | 1 |
| 52 | mdm2-inhibition | 1 |
| 53 | pathogen-recognition | 1 |
| 54 | 'horizon | 1 |
| 55 | rizzo | 2 |
| 56 | p97/vcp | 2 |
| 57 | post-deep | 1 |
| 58 | 5hre-sv40mp | 1 |
| 59 | guided-behavior | 1 |
| 60 | during-behavior | 1 |
| 61 | cephalosporins/quinolones | 1 |
| 62 | system-is | 1 |
| 63 | mmis | 1 |
| 64 | multitrials | 1 |
| 65 | protiens | 1 |
| 66 | cin3/cancers | 1 |
| 67 | multicargotransporters | 1 |
| 68 | cyp2j2/eets | 1 |
| 69 | -substituents | 1 |
| 70 | ceratophyus | 1 |
| 71 | speed/set | 1 |
| 72 | foment | 2 |
| 73 | spa-treatment | 1 |
| 74 | malnet-treatment | 1 |
| 75 | manifest | 827 |
| 76 | whithout | 1 |
| 77 | medication-review | 1 |
| 78 | low-average/low | 1 |
| 79 | favorably | 749 |
| 80 | unfavorably | 31 |
| 81 | favourably | 336 |
| 82 | unfavourably | 18 |
| 83 | adversely | 1,252 |
| 84 | aversively | 1 |
| 85 | benefically | 1 |
| 86 | allele-specifically | 2 |
| 87 | pleiotropically | 2 |
| 88 | non-homeostatically | 1 |
| 89 | beneficially | 176 |
| 90 | materially | 86 |
| 91 | detrimentally | 25 |
| 92 | most-commonly | 1 |
| 93 | necessarly | 1 |
| 94 | deleteriously | 12 |
| 95 | here-significantly | 1 |
| 96 | predminantly | 1 |
| 97 | unduly | 30 |
| 98 | deficity | 1 |
| 99 | reworkability | 1 |
| 100 | negative-polarity | 1 |
| 101 | hyperdensity/hyperintensity | 1 |
| 102 | milligravity | 1 |
| 103 | stress-reactivity | 2 |
| 104 | 14-3-3ɛ/ζ | 1 |